Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

SP4206

From Wikipedia, the free encyclopedia

SP4206
Identifiers
  • 5-[[2,3-dichloro-4-[5-[1-[2-[[(2R)-2-(diaminomethylideneamino)-4-methylpentanoyl]amino]acetyl]piperidin-4-yl]-1-methylpyrazol-3-yl]phenoxy]methyl]furan-2-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
ChEBI
ChEMBL
Chemical and physical data
FormulaC30H37Cl2N7O6
Molar mass662.57 g·mol−1
3D model (JSmol)
  • CC(C)C[C@H](C(=O)NCC(=O)N1CCC(CC1)C2=CC(=NN2C)C3=C(C(=C(C=C3)OCC4=CC=C(O4)C(=O)O)Cl)Cl)N=C(N)N
  • InChI=1S/C30H37Cl2N7O6/c1-16(2)12-21(36-30(33)34)28(41)35-14-25(40)39-10-8-17(9-11-39)22-13-20(37-38(22)3)19-5-7-23(27(32)26(19)31)44-15-18-4-6-24(45-18)29(42)43/h4-7,13,16-17,21H,8-12,14-15H2,1-3H3,(H,35,41)(H,42,43)(H4,33,34,36)/t21-/m1/s1
  • Key:VNZHOIDQBPFEJU-OAQYLSRUSA-N

SP4206 is an experimental drug which is described as a small molecule protein-protein interaction inhibitor. It binds with high affinity to interleukin-2 at the precise residues which usually mediate binding between interleukin-2 and the IL-2 receptor, thereby preventing binding and blocking the action of interleukin-2 in the body. Interleukin-2 is a cytokine signalling molecule with an important role in the function of the immune system, and most medical interest has been in enhancing interleukin-2 activity for the treatment of cancer. However, it is also involved in some autoimmune disease processes, and blocking interleukin-2 activity with SP4206 has been researched for the treatment of atopic asthma, which is commonly associated with elevated interleukin-2 levels.[1][2][3][4][5]

References

[edit]
  1. Thanos CD, DeLano WL, Wells JA (October 2006). "Hot-spot mimicry of a cytokine receptor by a small molecule". Proceedings of the National Academy of Sciences of the United States of America. 103 (42): 15422–15427. Bibcode:2006PNAS..10315422T. doi:10.1073/pnas.0607058103. PMC 1592646. PMID 17032757.
  2. Pieraccini S, De Gonda R, Sironi M (2011). "Molecular modeling of the inhibition of protein–protein interactions with small molecules: The IL2–IL2Rα case". Chemical Physics Letters. 517 (4–6): 217–222. Bibcode:2011CPL...517..217P. doi:10.1016/j.cplett.2011.10.044.
  3. Accordino SR, Morini MA, Sierra MB, Fris JA, Appignanesi GA, Fernández A (July 2012). "Wrapping mimicking in drug-like small molecules disruptive of protein-protein interfaces". Proteins. 80 (7): 1755–1765. doi:10.1002/prot.24069. hdl:11336/64004. PMID 22422633.
  4. Majumdar S, Ghosh A, Saha S (2018). "Modulating Interleukins and their Receptors Interactions with Small Chemicals Using In Silico Approach for Asthma". Current Topics in Medicinal Chemistry. 18 (13): 1123–1134. doi:10.2174/1568026618666180801092839. PMID 30068279.
  5. Shan Y, Mysore VP, Leffler AE, Kim ET, Sagawa S, Shaw DE (March 2022). "How does a small molecule bind at a cryptic binding site?". PLOS Computational Biology. 18 (3) e1009817. Bibcode:2022PLSCB..18E9817S. doi:10.1371/journal.pcbi.1009817. PMC 8893328. PMID 35239648.